Literature DB >> 20605624

Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels.

Bruna de Moraes Mazetto, Fernanda Loureiro Andrade Orsi, Lucia Helena Siqueira, Tayana Bezerra de Mello, Erich Vinícius de Paula, Joyce Maria Annichino-Bizzacchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20605624     DOI： 10.1016/j.thromres.2010.04.019

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  5 in total

Review 1.  Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.

Authors:  Antonio Girolami; Elisabetta Cosi; Silvia Ferrari; Annamaria Lombardi; Fabrizio Fabris
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

Review 2.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

Review 3.  New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice.

Authors:  A Girolami; E Cosi; S Ferrari; A M Lombardi; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

4.  Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants.

Authors:  Benjamin J Samelson-Jones; Jonathan D Finn; Leslie J Raffini; Elizabeth P Merricks; Rodney M Camire; Timothy C Nichols; Valder R Arruda
Journal:  Blood Adv       Date:  2021-03-09

Review 5.  Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX).

Authors:  Antonio Girolami; Silvia Ferrari; Elisabetta Cosi; Claudia Santarossa; Maria Luigia Randi
Journal:  Clin Appl Thromb Hemost       Date:  2018-11-14       Impact factor: 2.389
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.